| Identification | Back Directory | [Name]
(1R,3S,5Z)-3-Hydroxy-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]cyclohexyl 2-bromoacetate | [CAS]
158983-23-4 | [Synonyms]
(1R,3S,5Z)-3-Hydroxy-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]cyclohexyl 2-bromoacetate | [Molecular Formula]
C29H45BrO4 | [MOL File]
158983-23-4.mol | [Molecular Weight]
537.57 |
| Hazard Information | Back Directory | [Uses]
VDX-111 is an analog of vitamin D. VDX-111 exhibits cytotoxicity in ovarian cancer cells through upregulation of RIPK1/RIPK3 pathway and induction of necroptosis. VDX-111 promotes expressions of cytokines and exhibits antitumor activity in mouse model[1]. | [References]
[1] Persenaire C, et al., VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. Mol Carcinog. 2024 Apr 1. DOI:10.1002/mc.23721 |
|
|